What You Should Know:
–BioIntelliSense announced it has entered into a strategic partnership with The Leukemia & Lymphoma Society (LLS) to incorporate the BioSticker™ platform in clinical trials of hematological cancer patients.
– The LLS clinical trials will include use of the BioSticker medical device for the continuous collection of vital sign and physiological data which includes temperature, heart rate, respiratory rate at rest, activity level and body position. The BioSticker data services and advanced analytics will be used by LLS to correlate symptoms to treatment.
– The BioSticker is the first FDA-cleared single-use medical device that enables 30 days of continuous vital signs monitoring. The BioIntelliSense medical grade Data-as-a-Service (DaaS) platform and FDA 510(k) Class II medical wearable device provides a new standard for Remote Patient Monitoring (RPM), by combining an effortless patient experience with medical grade clinical accuracy, for cost-effective virtual trials.